Using BAC water beyond 28 days significantly increases the risk of contamination
Badretdinov, D., Kalimullina, L., & Zefirov, A
Day 16 dose change: the mid-cycle step up is easy to forget at home
Compounded prescription topicals contain these actives at 30 to 60 times the concentration of mass-market OTC serums
Use a Papaya Enzymebased cleanser or mask 23 times a week to exfoliate dull skin and brighten pigmentation

Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
